| Autor: |
Duong-Quy, Sy, Huynh-Truong-Anh, Duc, Nguyen-Quang, Tien, Nguyen-Thi-Kim, Thanh, Tran-Ngoc-Anh, Thuy, Nguyen-Van-Hoai, Nam, Do-Thi-Thu, Mai, Nguyen-Van, Tinh, Tang-Thi-Thao, Tram, Nguyen-Tuan, Anh, Nguyen-Van, Toi, Tran-Xuan, Quynh, Vu-Tran-Thien, Quan, Trinh-Du, The, Tran-Thai, Tuan, Nguyen-Duy, Thai, Tran-Van, Huong, Vo-Thi-Kim, Anh |
| Předmět: |
|
| Zdroj: |
Pulmonary Therapy; Jun2023, Vol. 9 Issue 2, p271-280, 10p |
| Abstrakt: |
Post-vaccination adverse reactions have been reported with varying symptoms and severity owing to research and production time pressures during the coronavirus disease 2019 (COVID-19) pandemic. In this article, we report a rare case of Guillain–Barré syndrome (GBS) in a patient with COVID-19 with acute respiratory distress syndrome (ARDS) after receiving Sinopharm's Vero Cell vaccine (China). The patient who was initially negative for COVID-19 was diagnosed with GBS based on paralysis that developed from the lower extremities to the upper extremities, as confirmed by cytoalbuminologic dissociation in the cerebrospinal fluid. The patient's condition worsened with ARDS caused by COVID-19 infection during the hospital stay, and SpO2 decreased to 83% while receiving oxygen through a non-rebreather mask (15 l/min) on day 6. The patient was treated with standard therapy for severe COVID-19, invasive mechanical ventilation, and five cycles of therapeutic plasma exchange (TPE) with 5% albumin replacement on day 11 due to severe progression. The patient was weaned off the ventilator on day 28, discharged on day 42, and was completely healthy after 6 months without any neurological sequelae until now. Our report showed the potential of TPE for GBS treatment in critically ill patients with COVID-19 after COVID-19 vaccination. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
